TRT on TikTok: separating real benefits from bro-science

What did @scott_otey actually say?

Scott Otey, who says he owns clinics in St. Louis and runs a nationwide telehealth operation, opened with a broad claim: TikTok is a "mecca of misinformation" on TRT. He positioned himself as a corrective voice, promising to answer questions based on his clinical experience. He did not make specific medical claims in this clip. The video is essentially an introduction, an offer to field questions rather than a lecture.

That framing matters for how we evaluate this. There are no dosing claims to dissect, no mechanistic assertions to cross-reference against the literature. What we have is a credentialing statement and a promise. Those deserve scrutiny too.

Does the science back this up?

On the core premise, yes. TikTok does have a documented misinformation problem in the hormone and men's health space. A 2023 analysis published in Andrology (Ohlander et al., 2023) found that a significant proportion of TRT-related social media content contained inaccurate or exaggerated claims about benefits, while downplaying risks like erythrocytosis, cardiovascular effects, and fertility suppression.

The claim that clinical experience translates to better patient information is harder to evaluate. Owning a clinic does not automatically confer evidence-based expertise. Some direct-to-consumer testosterone clinics have faced scrutiny for aggressive prescribing patterns that prioritize optimization over clinical indication. A 2020 study in JAMA Internal Medicine (Bhatt et al., 2020) found that many men initiating testosterone therapy through commercial channels did not meet traditional diagnostic criteria for hypogonadism. Experience can cut both ways.

What did they get wrong (or right)?

He got the broad diagnosis right. TikTok's TRT content skews toward anecdote, supplement promotion, and dose-fishing in the comments. The platform's algorithm rewards engagement, not accuracy, and men asking about testosterone are a commercially valuable audience. Calling that out is fair and overdue.

What's missing is self-awareness. A clinic owner with a national telehealth footprint has a financial stake in TRT adoption. That does not make his information wrong, but it does mean the conflict of interest should be disclosed, and it was not here. The Federal Trade Commission has increasingly scrutinized health influencers who blend clinical authority with commercial interest without clear disclosure. The line between education and marketing gets thin fast in this space.

He also mispronounced the therapy name as "Tisha Ashman placement therapy," which is clearly a self-aware joke. Not a clinical error, but worth noting for context.

What should you actually know?

TRT is a legitimate, FDA-regulated treatment for hypogonadism, defined by consistently low serum testosterone paired with symptoms. The Endocrine Society guidelines (Bhasin et al., 2018, Journal of Clinical Endocrinology and Metabolism) recommend two morning measurements below 300 ng/dL plus clinical symptoms before initiating therapy. That threshold matters. Starting testosterone based on symptoms alone, or based on a number that falls in a gray zone, is not standard of care.

Social media has real effects on prescribing demand. A 2021 survey in Sexual Medicine found that men who sought testosterone therapy after online research were significantly more likely to report unrealistic expectations about outcomes. Content creators, regardless of their credentials, shape those expectations. That is why source credibility, and conflict of interest transparency, matters as much as factual accuracy.

If you are evaluating a TRT provider, whether in a clinic or through a telehealth app, ask whether they require two fasting morning labs before prescribing, whether they monitor hematocrit and PSA, and whether they discuss fertility effects upfront. Those are the questions that separate evidence-based practice from hormone optimization marketing.